Here are four observations:
1. MACI is intended for the treatment of focal chondral cartilage defects in the knee.
2. MACI — matrix-applied characterized autologous cultured chondrocytes — is a third-generation autologous chondrocyte implantation product.
3. MACI was the first tissue-engineered product approved under the advanced therapy medicinal product guidelines by the European Commission.
4. Vericel is a developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions.
More articles on devices:
Blue Belt Technologies’s STRIDE knee system used in 1k procedures — 5 quick facts
Integra LifeSciences, Smith & Newphew, NuVasive & more — 14 key notes
Smith & Nephew voluntarily removes BIRMINGHAM HIP Resurfacing System components: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
